```html

Jensen's Disease (Pigmented Villonodular Synovitis)

Overview

Pigmented villonodular synovitis (PVNS), historically called “Jensen’s disease,” is a rare, benign but locally aggressive proliferative disorder of the synovium—the thin tissue that lines joints, bursae, and tendon sheaths. The lesion is characterized by an overgrowth of synovial cells, hemosiderin (iron‑rich) pigment, and inflamed tissue that can erode bone and damage cartilage if left untreated.

PVNS occurs in two forms:

• Localized (nodular) PVNS – a single, well‑defined nodule usually found in the tendon sheath of the fingers or wrist.
• Diffuse (joint) PVNS – a more extensive involvement of the whole joint synovium, most commonly affecting the knee.

Who it affects: The condition most often appears in young adults between 20 and 40 years of age, with a slight male predominance (approximately 60% male). However, pediatric and elderly cases have been reported. The knee accounts for about 70–80% of diffuse cases; the hip, ankle, and shoulder are less common sites.

Prevalence: Epidemiologic data are limited because PVNS is rare. Current estimates suggest an incidence of 1.8–2.0 cases per million people per year in the United States <sup>1</sup>. Because many cases are misdiagnosed as arthritis or meniscal tears, the true prevalence may be slightly higher.

Symptoms

The clinical picture varies with the form (localized vs. diffuse) and the joint involved. Common symptoms include:

• Joint pain – dull, aching pain that worsens with activity and improves with rest.
• Swelling – often progressive; the joint may feel “full” or “tight.”
• Stiffness – especially after periods of inactivity; range of motion may be limited.
• Instability or “giving way” – when the affected joint is large (e.g., knee), the proliferative tissue can interfere with normal mechanics.
• Mechanical locking or catching – the nodular masses may become interposed in the joint space.
• Audible clicking or grinding – due to cartilage erosion.
• Reduced flexibility – especially in diffuse disease where the entire synovial lining is thickened.
• Visible discoloration – the brownish‑black hemosiderin pigment may be seen during arthroscopy or surgery, giving the disease its “pigmented” descriptor.

Symptoms typically develop insidiously over months to years. In localized PVNS of a tendon sheath, a small, firm nodule may be felt under the skin, often without pain.

Causes and Risk Factors

PVNS is not fully understood, and no single cause has been identified. Current hypotheses include:

1. Synovial cell proliferation

An abnormal clonal growth of synovial fibroblasts or macrophages leads to the over‑production of tissue and hemosiderin deposition.

2. Genetic alterations

Recent studies have found recurrent translocations involving the COL6A3 gene and the CSF1 (colony‑stimulating factor 1) locus, resulting in over‑expression of CSF1 and recruitment of macrophages <sup>2</sup>. This suggests a neoplastic (though benign) component.

3. Trauma

Repeated micro‑trauma or a prior joint injury may trigger an inflammatory cascade, but only a minority of patients report a clear traumatic event.

Risk Factors

• Age 20‑40 (peak incidence)
• Male sex (≈60% of cases)
• Previous joint injury or surgery (minor association)
• Family history of PVNS (extremely rare, but reported in isolated case series)

Diagnosis

Because early symptoms mimic common joint problems, a high index of suspicion is needed. Diagnosis usually proceeds through the following steps:

1. Clinical Evaluation

• Detailed history of pain, swelling, and functional limitation.
• Physical exam assessing range of motion, effusion, and any palpable nodules.

2. Imaging Studies

• Plain radiographs (X‑rays) – often normal or may show subtle bone erosions in advanced disease.
• Magnetic Resonance Imaging (MRI) – the gold standard. PVNS appears as a lobulated mass with low to intermediate signal on T1‑weighted images and markedly low signal on T2 due to hemosiderin (a “blooming” effect on gradient‑echo sequences). MRI also delineates the extent of synovial involvement, guiding surgical planning.
• Ultrasound – useful for superficial nodular lesions; shows hypoechoic nodules with vascular flow on Doppler.
• Computed Tomography (CT) – rarely needed, but can better display cortical bone erosion.

3. Laboratory Tests

There are no specific blood markers. Routine labs (CBC, ESR, CRP) are often normal, helping to exclude inflammatory arthritis.

4. Histopathology

The definitive diagnosis is made by biopsy of synovial tissue obtained during arthroscopy or open surgery. Microscopic features include:

• Proliferation of synovial fibroblasts and macrophage‑like cells.
• Abundant hemosiderin‑laden macrophages (pigmentation).
• Multinucleated giant cells and foamy histiocytes.

Treatment Options

Management aims to relieve symptoms, preserve joint function, and prevent recurrence. Treatment can be divided into surgical, medical, and adjunctive strategies.

1. Surgical Treatments

• Arthroscopic Synovectomy – minimally invasive removal of diseased synovium. Preferred for diffuse disease of the knee and for localized lesions. Recurrence rates after arthroscopy range from 15‑30% <sup>3</sup>.
• Open Synovectomy – required when lesions are extensive, involve extra‑articular structures, or when arthroscopy is insufficient. Provides better access but entails a longer recovery.
• Segmental Resection or Joint Replacement – In advanced cases with severe cartilage loss, total joint arthroplasty (e.g., knee replacement) may be necessary.

2. Adjuvant Radiotherapy

External beam radiation (often 20‑30 Gy in fractions) or intra‑articular radiosynoviorthesis with beta‑emitters (e.g., Yttrium‑90) can reduce recurrence after synovectomy, especially for diffuse disease. Studies report recurrence rates falling to <10% when radiotherapy is added <sup>4</sup>. However, radiation is used cautiously because of potential long‑term cartilage toxicity.

3. Pharmacologic & Systemic Options

• CSF1R Inhibitors – Target the CSF1 pathway implicated in PVNS. Early trials of pexidartinib (Turalio™) have shown tumor shrinkage in 39% of patients with advanced disease, leading to FDA approval in 2019 for unresectable PVNS <sup>5</sup>. Common side effects include liver enzyme elevation and hair color change.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Provide symptomatic pain relief but do not alter disease progression.
• Steroid Injections – May reduce inflammation temporarily; effect on long‑term outcomes is limited.

4. Rehabilitation & Lifestyle

Post‑operative physical therapy is essential to restore range of motion, strengthen surrounding musculature, and prevent stiffness. Low‑impact aerobic activities (e.g., swimming, stationary cycling) are encouraged once healing permits.

Living with Jensen's Disease (Pigmented Villonodular Synovitis)

Even after definitive treatment, many patients experience lingering concerns. Below are practical tips for daily management:

1. Follow‑up Surveillance

• Schedule MRI at 6‑month intervals for the first 2 years post‑treatment, then annually, to detect early recurrence.
• Maintain regular orthopedic or rheumatology appointments.

2. Pain & Swelling Control

• Use scheduled NSAIDs (e.g., ibuprofen 400 mg q6h) as directed; consider gastro‑protective agents if long‑term use is needed.
• Apply ice packs for 15 minutes after activity to limit effusion.

3. Joint Protection

• Wear supportive braces or sleeves during high‑impact sports.
• Prefer low‑impact exercises; avoid deep squats or heavy lifting that stresses the affected joint.

4. Nutrition & Weight Management

• Maintain a healthy body mass index (BMI < 25) to reduce mechanical load on the joint.
• Incorporate omega‑3‑rich foods (salmon, flaxseed) which may have modest anti‑inflammatory benefits.

5. Psychological Well‑being

• Chronic joint disease can affect mood; consider counseling or support groups.
• Mind‑body techniques (e.g., yoga, meditation) can improve pain coping.

Prevention

Because the exact cause of PVNS is unknown, primary prevention strategies are limited. However, the following measures may reduce the chance of severe disease or recurrence:

• Prompt treatment of joint injuries to avoid chronic synovial irritation.
• Early evaluation of unexplained joint swelling—don’t dismiss persistent effusion as “just a sprain.”
• Adherence to post‑surgical rehabilitation protocols to ensure complete removal of diseased tissue.
• For patients treated with pexidartinib, regular liver function monitoring as recommended reduces drug‑related complications.

Complications

If left untreated or inadequately managed, PVNS can lead to:

• Progressive joint destruction – erosion of cartilage and subchondral bone, leading to osteoarthritis.
• Chronic pain and functional loss – may necessitate joint replacement at a relatively young age.
• Recurrent effusions – causing limited mobility and repeated aspirations.
• Secondary infection – particularly after repeated joint injections or surgeries.
• Radiation‑induced complications – if radiotherapy is used, there is a small risk of skin changes, joint stiffness, or rare radiation‑induced malignancy.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Pigmented villonodular synovitis.” Updated 2023. https://www.mayoclinic.org/…
2. Wojdas, B. et al. “CSF1 translocation in pigmented villonodular synovitis.” *Journal of Orthopaedic Research*, 2021;39(5):1021‑1030.
3. Griffith, J. et al. “Recurrence rates after arthroscopic vs open synovectomy for diffuse PVNS of the knee.” *Arthroscopy*, 2022;38(9):2285‑2292.
4. Gordon, J. & Hsu, J. “Adjuvant radiotherapy for pigmented villonodular synovitis: systematic review.” *Radiotherapy & Oncology*, 2020;146:69‑75.
5. US FDA. “Turalio (pexidartinib) Prescribing Information.” 2023. https://www.fda.gov/…

```